MiniMed Group, Inc. reported fiscal 2026 revenue of $3102M, up 14.2% from $2715M a year earlier, while the company recorded a net loss attributable to the company of $(333)M and diluted loss per share of $(1.30), both wider than in FY 2025 — 10-K Summary.
Financial Highlights
- Revenue was $3,102M for FY 2026, compared with $2,715M in FY 2025; YoY change 14.2%.
- Net income was a loss of $(333)M for FY 2026, compared with a loss of $(213)M in FY 2025 (worsened $120M).
- Diluted EPS was $(1.30) for FY 2026, compared with $(0.84) in FY 2025 (more negative).
Business Highlights
- Revenue growth of 14% to $3.1B was driven by increased continuous glucose monitoring (CGM) and consumables volumes, with CGM attachment rate rising to 66% and boosting recurring consumables revenue.
- Product momentum included FDA clearance and U.S. launches of MiniMed Flex and MiniMed Go, with ongoing global rollouts expanding market availability.
- Operationally, the company incurred a one‑time R&D royalty charge and write‑offs on a manufacturing contract while ramping Simplera and Simplera Sync production.
- New pump sales remained stable at roughly 145k units, with higher CGM attachment supporting ecosystem adoption and recurring revenue streams.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.